OK, my honest estimation. First impression is ... it doesn't sound like a company that plans on going out of business anytime soon.
YES, I know, at this point, it is still just talk and hot air, but you have to admit, a lot of it sure sounded good.
"No dose limiting toxicities, cytokine release syndrome or neurotoxicity were observed. The results were consistent with the safety data observed in more than 150 patients treated in the Phase 1/2 studies at the Baylor College of Medicine.
1 MRD+ patient became MRD- after infusion with MT-401.
Immuno-monitoring data indicates the evidence of epitope spreading after infusion of MT-401 in the patient who converted from MRD+ to MRD-."
...........SOUNDS GOOD.
"The new nine-day manufacturing process enables increased antigen specificity and diversity, which has exhibited a strong linear correlation to anti-tumor activity in vitro. The new process produces a patient product that is four times more potent, with the potential to greatly improve tumor killing."
............SOUNDS GREAT
"Mr. Hoang continued: “Further, we are pleased to announce a planned expansion of our pipeline into pancreatic cancer, our first Company-sponsored trial evaluating MultiTAA cell therapy for the treatment of solid tumors, and a Company-sponsored Phase 1 trial in lymphoma."
..........BUT BUT BUT .... "but beginning any additional clinical trial is subject to the receipt of additional funding:"
ALSO IN THE FUTURE:
"Patient-specific product candidates
MT-601, a six-antigen product, for the treatment of pancreatic cancer and lymphoma
The Company intends to file Investigational New Drug applications (INDs) for MT-601 in pancreatic cancer and lymphoma in 2022 and expects to initiate these trials in 2023
Off-the-shelf (OTS) product candidates
Patients will be dosed using “banked” products based on human leukocyte antigen (HLA) matching
The OTS platform is designed to eliminate manufacturing wait time and patient product can be shipped to patients immediately
High scalability where one donor has the potential to provide more than 100 patient products
An OTS program in AML is already approved under the Company’s current Phase 2 AML IND. The Company is currently in the process of developing its patient cell bank inventory and expects to dose the first patient in 2023.
The Company expects to expand OTS clinical trials in other hematological malignancies and solid tumors
Preclinical / development activities
Analyzing potential of a 12-antigen product
Assessing potential of combination therapies for MT-401 and MT-601"
............."but beginning any additional clinical trial is subject to the receipt of additional funding:"
"but beginning any additional clinical trial is subject to the receipt of additional funding:"
Most sounded good to me but also sounded like they will need a lot more $"s to do what they just said.
Any dilution or sale anywhere near this sick low price valuation will kill investors.
Need to with a partner on one trial so the upfront payment part can help fund the beginnings of the future plans. The milestone payments will come later and help later, but for now, no dilution.
